9/30
10:58 am
nktr
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
9/30
10:54 am
nktr
Rating for NKTR
Medium
Report
Rating for NKTR